tavneos

tavneos: developed by 1 company · 1 FDA decision. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
ChemoCentryx, Inc. (CCXI)Preclinical

FDA Decisions

Approval1 INDICATIONS AND USAGE TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use. TAVNEOS is a complement 5a receptor (C5aR) antagonist indicated as an adjunctive treatment of adult patients with severe active anti-n(CCXI)

Frequently asked questions

Who is developing tavneos?

tavneos is being developed by ChemoCentryx, Inc..

What is tavneos's latest FDA decision?

The most recent tracked FDA decision for tavneos is Approval for 1 INDICATIONS AND USAGE TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use. TAVNEOS is a complement 5a receptor (C5aR) antagonist indicated as an adjunctive treatment of adult patients with severe active anti-n, dated October 7, 2021.

Get deeper analysis on tavneos

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    tavneos — Drug Pipeline, Trials & FDA Status | BioSniper